Worldquant Millennium Advisors LLC Makes New $127.49 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Worldquant Millennium Advisors LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 121,275 shares of the biopharmaceutical company’s stock, valued at approximately $127,489,000. Regeneron Pharmaceuticals comprises approximately 0.9% of Worldquant Millennium Advisors LLC’s investment portfolio, making the stock its 22nd largest position. Worldquant Millennium Advisors LLC owned approximately 0.11% of Regeneron Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. SteelPeak Wealth LLC grew its holdings in shares of Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 692 shares during the last quarter. Mizuho Securities USA LLC boosted its position in Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares during the period. Tri Locum Partners LP grew its stake in Regeneron Pharmaceuticals by 104.5% in the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after acquiring an additional 8,949 shares in the last quarter. Simplify Asset Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after acquiring an additional 3,231 shares during the period. Finally, Catalytic Wealth RIA LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $1,334,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.8 %

Shares of REGN stock opened at $767.90 on Friday. The stock’s fifty day moving average price is $882.14 and its 200 day moving average price is $1,013.01. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20. The company has a market cap of $84.38 billion, a price-to-earnings ratio of 19.00, a price-to-earnings-growth ratio of 2.89 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Analysts Set New Price Targets

A number of brokerages recently issued reports on REGN. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Citigroup began coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,107.29.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.